Saleh Mohebbi, Mohammadsadegh Zabihidan, Ali Omidvari, Mehdi Abrishami
{"title":"Post-COVID-19 Maxillary Bony Sequestration: A Case Report on Mucormycosis Challenges","authors":"Saleh Mohebbi, Mohammadsadegh Zabihidan, Ali Omidvari, Mehdi Abrishami","doi":"10.1002/ccr3.71080","DOIUrl":null,"url":null,"abstract":"<p>COVID-19-associated mucormycosis (CAM) is a severe opportunistic infection, typically affecting immunocompromised patients. Maxillary bony sequestration as a delayed complication in immunocompetent individuals is rare, highlighting diagnostic and therapeutic challenges. A 31-year-old male with no comorbidities presented in September 2021 with COVID-19 pneumonia (Delta variant), treated with dexamethasone and remdesivir. In October 2021, he developed right maxillary hypoesthesia and cheek swelling. Nasal endoscopy and biopsy confirmed mucormycosis, managed with liposomal amphotericin B and endoscopic debridement. In February 2023, malodor and tooth loosening prompted imaging, revealing maxillary bony sequestration due to fungal-induced vascular thrombosis and necrosis, treated with surgical resection and prosthetic reconstruction. One-month follow-up (March 2023) showed no recurrence or complications, though the short follow-up limits long-term conclusions. This case underscores maxillary bony sequestration as a rare, delayed complication of CAM, even in immunocompetent patients. Persistent symptoms like malodor or tooth mobility warrant imaging and surgical evaluation. Long-term follow-up is crucial to detect and manage such sequelae.</p>","PeriodicalId":10327,"journal":{"name":"Clinical Case Reports","volume":"13 10","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485291/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ccr3.71080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
COVID-19-associated mucormycosis (CAM) is a severe opportunistic infection, typically affecting immunocompromised patients. Maxillary bony sequestration as a delayed complication in immunocompetent individuals is rare, highlighting diagnostic and therapeutic challenges. A 31-year-old male with no comorbidities presented in September 2021 with COVID-19 pneumonia (Delta variant), treated with dexamethasone and remdesivir. In October 2021, he developed right maxillary hypoesthesia and cheek swelling. Nasal endoscopy and biopsy confirmed mucormycosis, managed with liposomal amphotericin B and endoscopic debridement. In February 2023, malodor and tooth loosening prompted imaging, revealing maxillary bony sequestration due to fungal-induced vascular thrombosis and necrosis, treated with surgical resection and prosthetic reconstruction. One-month follow-up (March 2023) showed no recurrence or complications, though the short follow-up limits long-term conclusions. This case underscores maxillary bony sequestration as a rare, delayed complication of CAM, even in immunocompetent patients. Persistent symptoms like malodor or tooth mobility warrant imaging and surgical evaluation. Long-term follow-up is crucial to detect and manage such sequelae.
期刊介绍:
Clinical Case Reports is different from other case report journals. Our aim is to directly improve global health and increase clinical understanding using case reports to convey important best practice information. We welcome case reports from all areas of Medicine, Nursing, Dentistry, and Veterinary Science and may include: -Any clinical case or procedure which illustrates an important best practice teaching message -Any clinical case or procedure which illustrates the appropriate use of an important clinical guideline or systematic review. As well as: -The management of novel or very uncommon diseases -A common disease presenting in an uncommon way -An uncommon disease masquerading as something more common -Cases which expand understanding of disease pathogenesis -Cases where the teaching point is based on an error -Cases which allow us to re-think established medical lore -Unreported adverse effects of interventions (drug, procedural, or other).